Stockscreener 앱 받기
97.97
0.48%
-0.33
전일 마감가:
$98.30
열려 있는:
$98.49
하루 거래량:
638.49K
Relative Volume:
0.39
시가총액:
$47.15B
수익:
$9.91B
순이익/손실:
$1.02B
주가수익비율:
47.79
EPS:
2.05
순현금흐름:
$665.00M
1주 성능:
+2.63%
1개월 성능:
+16.71%
6개월 성능:
+5.83%
1년 성능:
+22.95%
1일 변동 폭
$97.86
$98.56
1주일 범위
$95.30
$99.20
52주 변동 폭
$79.63
$101.10
Alcon Inc Stock (ALC) Company Profile
ALC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
97.98 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
534.09 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.10 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
240.76 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.13 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 재확인 | Needham | Buy |
| 2025-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-24 | 재확인 | Needham | Buy |
| 2025-01-10 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | 재확인 | Needham | Buy |
| 2024-11-12 | 재확인 | Needham | Buy |
| 2024-10-10 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-10 | 개시 | Goldman | Buy |
| 2024-03-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | 개시 | Bernstein | Outperform |
| 2023-12-18 | 다운그레이드 | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | 업그레이드 | Societe Generale | Sell → Hold |
| 2022-12-22 | 개시 | Mizuho | Buy |
| 2022-11-17 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-08-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-05-13 | 재개 | Credit Suisse | Outperform |
| 2022-05-12 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | 개시 | Needham | Buy |
| 2022-03-11 | 개시 | BofA Securities | Buy |
| 2022-01-18 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 개시 | Oppenheimer | Perform |
| 2021-07-14 | 개시 | Deutsche Bank | Buy |
| 2021-05-06 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-03-22 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-11-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-07-06 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-07-06 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Argus | Hold → Buy |
| 2020-03-24 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-03-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-26 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-01-08 | 개시 | Argus | Hold |
| 2019-10-29 | 개시 | Stephens | Equal-Weight |
| 2019-08-21 | 재확인 | BofA/Merrill | Neutral |
| 2019-06-24 | 개시 | SVB Leerink | Mkt Perform |
| 2019-06-14 | 개시 | BTIG Research | Neutral |
| 2019-05-10 | 개시 | Robert W. Baird | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
모두보기
Alcon Inc 주식(ALC)의 최신 뉴스
Institutional investors are Alcon Inc.'s (VTX:ALC) biggest bettors and were rewarded after last week's CHF1.2b market cap gain - simplywall.st
Do Options Traders Know Something About Alcon Stock We Don't? - Nasdaq
RBC Bets On Alcon's Growth With Continued Outperform Rating - Finimize
RBC Keeps Alcon at Outperform Ahead of Q1 Results - marketscreener.com
Alcon (ALC) Gets a Buy from RBC Capital - The Globe and Mail
Alcon Rolls Out Unity Vitreoretinal and Cataract Surgery Systems - Medical Product Outsourcing
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior E - GuruFocus
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS - marketscreener.com
Corneal Topographers Market Deep Research 2025-2032 | Alcon plc., Abbott Laboratories, Topcon Corporation - openPR.com
WCO & Alcon Dry Eye Wheel launches in French - childrennow.co.uk
Village Roadshow’s $417.5 Million Stalking Horse Deal Approved - Bloomberg.com
Alcon Entertainment Appoints Former MGM Exec Steven Johnson As EVP, Head Of Physical Production - IMDb
Alcon lines up product launches in India, bets on rising demand for advanced eye care - MSN
Lobbying Update: $150,000 of ALCON VISION LLC lobbying was just disclosed - Nasdaq
Aniridia Treatment Market Is Going to Boom | Major Giants Alcon, Santen Pharmaceutical, Johnson & Johnson Vision - openPR.com
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital - Yahoo Finance
Alcon: A Clear Vision, But Fully Valued (NYSE:ALC) - Seeking Alpha
GE HealthCare Hires Alcon Exec Jeannette Bankes as Patient Care Solutions CEO - Medical Product Outsourcing
High-level Milwaukee-area GE HealthCare exec to retire - The Business Journals
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC) - Insider Monkey
Tesla, Warner Bros fend off some claims in 'Blade Runner 2049' ad dispute - Reuters
Alcon (VTX:ALC) Seems To Use Debt Quite Sensibly - simplywall.st
Alcon Scoops Up Aurion Biotech With Intent of Advancing Ophthalmology Cell Therapy AURN001 - CGTLive®
US Tariffs Challenge Carl Zeiss Meditec And Smith & Nephew - Finimize
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 - Investing.com Canada
Alcon, Aurion Reach Accord in Dispute Over Public Offering - Bloomberg Law News
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 By Investing.com - Investing.com South Africa
Dr. Jeffrey Martin of SightMD Becomes One of the First on Long Island to Implant the new Clareon® PanOptix® Pro Lens by Alcon - PRWeb
Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
ALC Stock May Rise With the Introduction of PanOptix Pro in US - MSN
Alcon Introduces Clareon PanOptix Pro Intraocular Lens - Medical Product Outsourcing
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix - GuruFocus
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter – Company AnnouncementFT.com - Financial Times
Game-Changing Cataract Lens: Alcon's New PanOptix Pro Achieves Record 94% Light Efficiency - Stock Titan
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space - TradingView
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 - Investing.com Canada
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 By Investing.com - Investing.com South Africa
Alcon Inc (ALC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.21%
자본화:
|
볼륨(24시간):